Low-dose metronomic chemotherapy with cisplatin: Can it suppress angiogenesis in H22 hepatocarcinoma cells?

International Journal of Experimental Pathology

Volumn 91, Issue 1, 2010, Pages 10-16

  Shen, Fang Zhen ^a   Wang, Jing ^a   Liang, Jun ^a   Mu, Kun ^a   Hou, Ji Yuan ^a   Wang, Yan Tao ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Angiogenesis; Chicken chorio allantoic membrane; Cisplatin; H22 hepatocarcinoma; HUVECs

Indexed keywords

CISPLATIN; GELATINASE A; TETRAZOLIUM; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL DENSITY; CELL PROLIFERATION; CELL STRAIN HEPG2; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOW DOSE METRONOMIC CHEMOTHERAPY; LOW DRUG DOSE; MALE; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MAXIMUM TOLERATED DOSE; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; TIME FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74549208007     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2009.00684.x     Document Type: Article

References (21)

1. Albertsson P., Lennernäs B., Norrby K. (2006) On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol. 45, 144 155.
2. Assaraf Y.G. (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist. Updat. 9, 227 246.
3. Buckstein R., Kerbel R.S., Shaked Y. et al. (2006) High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin. Cancer Res. 12, 5190 5198.
4. Folkman J. (2003) Angiogenesis and apoptosis. Semin. Cancer Biol. 13, 159 167.
5. Franchi F., Grassi P., Ferro D. et al. (2007) Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. Eur. J. Cancer Care 16, 258 262.
6. Guo R.P., Zhong C., Shi M. et al. (2006) Expression and clinical significance of certain apoptosis and angiogenesis factors in hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 44, 1626 1630.
7. Klement H., St Croix B., Milsom C. et al. (2007) Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am. J. Pathol. 171, 1342 1351.
8. Lam T., Hetherington J.W., Greenman J., Little S., Maraveyas A. (2007) Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncol. 46, 1169 1177.
9. Li T., Li Y.G., Pu D.M. (2006) Matrix metalloproteinase-2 and -9 expression correlated with angiogenesis in human adenomyosis. Gynecol. Obstet. Invest. 62, 229 235.
10. Lu Q.B. (2007) Molecular reaction mechanisms of combination treatments of low-dose cisplatin with radiotherapy and photodynamic therapy. J. Med. Chem. 50, 2601 2604.
11. Moreira I.S., Fernandes P.A., Ramos M.J. (2007) Vascular endothelial growth factor (VEGF) inhibition - a critical review. Anticancer Agents Med. Chem. 7, 223 245.
12. Ozdogan O., Ertay T., Arslan G. et al. (2008) Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study Ann. Nucl. Med. 22, 357 362.
13. Ruggeri B., Singh J., Gingrich D. et al. (2003) CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 63, 5978 5991.
14. Sbovata S.M., Bettio F., Mozzon M. et al. (2007) Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy. J. Med. Chem. 50, 4775 4784.
15. Schweitzer V.G. (1993) Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103, 1 52.
16. Shaked Y., Ciarrocchi A., Franco M. et al. (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785 1787.
17. Spaner D.E., Masellis A. (2007) Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21, 53 60.
18. Tamura T., Fujita F., Tanimoto M. et al. (2002) Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice. J. Control. Release 80, 295 307.
19. Veale D.J. Fearon U. (2006) Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract. Res. Clin. Rheumatol. 20, 941 947.
20. Wu H., Chen H., Hu P.C. (2007) Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin. Lab. 53, 285 295.
21. Zhang Q., Chen X., Zhou J. et al. (2006) CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol. Ther. 5, 808 814.